Prospera Biotech Closes a €200,000 Financing Round

Prospera Biotech attracts new capital. The biotech startup promoted by the Miguel Hernández University of Elche (UMH) to develop products that care for sensitive skin by acting on the neurosensory system has closed a financing round of $224,000 (€200,000) from private capital.

This new contribution multiplies by five the capital of the company, which started its activity formulating neurocosmetics with an initial investment of $56,000 (€50,000), according to the Spanish company through a statement.

“This contribution will be a boost to accelerate the development of new products, especially a formulation for sensitive skin caused by oncology treatment that is at a very advanced stage of study and to consolidate the commercial network,” according to Marta García Escolano, CEO of Prospera Biotech.

Born2Invest’s team of journalists gathers the most interesting business news in a single mobile application. It’s impossible to keep up with everything you’re interested in, but our companion app will help you keep track of the important news. Our app is being updated throughout the day.

Prospera Biotech has launched three products in its first year of activity

Prospera Biotech formulates neurocosmetic solutions based on innovative active ingredients that act on the epidermal nerve endings developed by scientists at the Institute for Research, Development, and Innovation in Health Biotechnology (Idibe) of the UMH.

Idibe has spent more than twenty years studying the role of nociceptors (nerve endings of the neurological system located in the skin responsible for pain and itching) in skin pathologies, the mechanisms that activate them, and how to act on them to soothe them. This knowledge has helped Prospera Biotech to develop neurodermatological products that are an effective alternative to traditional care of sensitive skin, which is based largely on hydration and immunosuppression of people who suffer from it.

In its first year of activity, Prospera Biotech has already launched three products: Nocisens, Nocisens Intense, and Nocisens Baby, three creams that include neuromodulatory active ingredients that act directly on the nerve terminals responsible for itching, stinging and pain restoring their balance and, therefore, putting an end to these discomforts. These products are indicated in cases of sensitive skin with atopic tendencies, diaper rash, and other conditions that cause itching, stinging or pain, and represent a new alternative for the relief of the discomfort suffered by an increasing number of people in developed countries.

Among the new launches to be accelerated by this new financing are specific formulations for gynecological skin conditions, a product for skin with excessive sweating, and a cream to soothe the sensory discomfort generated as a result of chemotherapy treatment.

__

(Featured image by AdoreBeautyNZ via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.